Prescriber's Corner

Ziv-Aflibercept Use in Metastatic Colorectal Cancer

Mabel Rodriguez, PharmD

From Memorial Sloan-Kettering Cancer Center, New York, New York

The author has no conflicts of interest to disclose.

Correspondence to: Mabel Rodriguez, PharmD, Memorial Sloan-Kettering Clinical Pharmacy Department, 1265 York Avenue S-710, New York, NY 10065. E-mail: rodrigm3@mskcc.org


J Adv Pract Oncol 2013;4:348–352 | DOI: 10.6004/jadpro.2013.4.5.6 | © 2013 Harborside Press®


  

ABSTRACT

In August 2012, ziv-aflibercept (Zaltrap) was approved by the FDA for use in combination with FOLFIRI in certain oxaliplatin-refractory patients with mCRC. Read about the mechanism of action, key trials, and management strategies associated with this VEGF pathway targeted agent.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.